Many Gen Z-ers pursuing careers in healthcare to avoid AI-related workforce shrinkage will learn a hard lesson: Job security and job satisfaction are two very different things.

There’s no shortage of technically impressive AI applications for primary care. Yet these tools tend to lag well behind AI models aimed at clinical specialties when it comes to integration into routine practice.

The Varipulse PFA platform, which has already received FDA and CE mark approval, was linked to an adverse event rate of just 0.6%. 

New data out of ESC Congress 2025 suggest care teams can take a more minimalist approach during a majority of TAVR cases and only treat patients with local anesthesia. In some cases, however, sedation will still be necessary. 

FDA clears AI-powered glucose monitoring app. The clearance marks a first for an over-the-counter tool in this category.

Tech vendor Reveleer and policy analytics firm Mathematica released their 2025 State of Technology in Value-Based Care report, the findings of which show that AI adoption in healthcare is widespread—but integration is spotty. 

Most organizations trying out generative AI—a full 95%—are failing to receive a measurable return on the pilot investment. 

If three sticking points aren’t unstuck soon, older Americans won’t benefit much by the 1,000+ medical devices that, as of 2025, are both equipped with AI and cleared by the FDA.